HomeQuestion

Would you prescribe a GLP-1 receptor agonist for an obese patient with low to moderate cardiovascular risk but a high CAC score?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

How often do you recommend performing an advanced lipid panel for monitoring of lipid lowering therapy?

Under what clinical circumstances, if any, would you prescribe fenofibrate along with statin therapy?

Do you avoid the use of GLP-1 R agonist therapy for treatment of obesity in patients with known gastroparesis?

Would you consider transitioning patients older than 75 years of age with coronary disease from statins and/or other lipid-lowering agents to PCSK9 inhibitors given concerns for polypharmacy, provided their LDL levels remain at or below goal?

When do you think physicians should seriously consider prescribing PCSK9 inhibitors for the prevention of heart attack and stroke in people with ASCVD or diabetes, based on the results of the VESALIUS-CV trial?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.